Authors

• Elisa Barbieri (ORCID: https://orcid.org/0000-0003-0850-8784)
• Elisa Martín‐Merino (ORCID: https://orcid.org/0000-0002-3576-8605)
• Mar Martín‐Pérez (ORCID: https://orcid.org/0000-0002-5376-2549)
• Leire Leache (ORCID: https://orcid.org/0000-0003-2272-7086)
• Luis Carlos Saiz (ORCID: https://orcid.org/0000-0002-9143-5709)
• Elena Segundo (ORCID: https://orcid.org/0000-0001-6785-5888)
• Olaf H. Klungel (ORCID: https://orcid.org/0000-0002-5604-813X)
• Fabio Riefolo (ORCID: https://orcid.org/0000-0002-6762-2619)
• Belén Castillo‐Cano (ORCID: https://orcid.org/0000-0001-8280-7489)
• Davide Messina (ORCID: https://orcid.org/0000-0003-3813-5501)
• Dorieke Brink‐Kwakkel (ORCID: https://orcid.org/0000-0002-1826-3138)
• Rosa Gini (ORCID: https://orcid.org/0000-0002-6250-877X)
• Tiago Andres Vaz (ORCID: https://orcid.org/0000-0003-3125-0662)
• Carlo Alberto Bissacco (ORCID: https://orcid.org/0000-0001-6629-2198)
• Felipe Villalobos (ORCID: https://orcid.org/0000-0002-6907-8354)
• Roel Elbers

Institutions

• University of Mons (BE)
• University of Padua (IT)
• Utrecht University (NL)
• University Medical Center Utrecht (NL)
• Navarre Institute of Health Research (ES)
• Pharmo Institute (NL)
• Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
• Agencia Española de Medicamentos y Productos Sanitarios (ES)
• Community Health Partnership (US)
• Agenzia Regionale di Sanità della Toscana (IT)

Publication Details

Journal

Pharmacoepidemiology and Drug Safety

Published

2025-10-22

DOI

https://doi.org/10.1002/pds.70239

Primary Topic

SARS-CoV-2 and COVID-19 Research

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Universiteit Utrecht
• Agencia Española de Medicamentos y Productos Sanitarios